Treatment with tumor necrosis factor inhibitors and the risk of acute coronary syndromes in early rheumatoid arthritis

Acute Coronary Syndromes ◽

Tumor Necrosis ◽

Coronary Syndromes ◽

Is there a pharmacoeconomic argument supporting the use of tumor necrosis factor inhibitors in early rheumatoid arthritis?

Nature Clinical Practice Rheumatology ◽

10.1038/ncprheum0218 ◽

2006 ◽

Vol 2 (7) ◽

pp. 346-347 ◽

Cited By ~ 2

Author(s):

Arthur Kavanaugh

Keyword(s):

Rheumatoid Arthritis ◽

Tumor Necrosis Factor ◽

Tumor Necrosis ◽

Faculty Opinions recommendation of Patients with early rheumatoid arthritis who smoke are less likely to respond to treatment with methotrexate and tumor necrosis factor inhibitors: observations from the Epidemiological Investigation of Rheumatoid Arthritis and the Swedish Rheumatology Register cohorts.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.5664957.5637055 ◽

2010 ◽

Author(s):

Jiri Vencovsky ◽

Herman Mann

Keyword(s):

Rheumatoid Arthritis ◽

Tumor Necrosis Factor ◽

Tumor Necrosis ◽

Epidemiological Investigation ◽

AB0399 Reduced Risk of Acute Coronary Syndromes among Rheumatoid Arthritis Patients with Good Response on Tumor Necrosis Factor Inhibition

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2014-eular.5223 ◽

2014 ◽

Vol 73 (Suppl 2) ◽

pp. 938.3-939

Author(s):

L. Ljung ◽

L. Jacobsson ◽

S. Rantapää-Dahlqvist ◽

J. Askling

Keyword(s):

Rheumatoid Arthritis ◽

Tumor Necrosis Factor ◽

Acute Coronary Syndromes ◽

Tumor Necrosis ◽

Tumor Necrosis Factor Inhibition ◽

Coronary Syndromes ◽

Necrosis Factor ◽

Reduced Risk

Delayed treatment with tumor necrosis factor inhibitors in incomplete responders to synthetic disease-modifying anti-rheumatic drugs shows an excellent effect in patients with very early rheumatoid arthritis with poor prognosis factors

Modern Rheumatology ◽

10.3109/s10165-011-0511-y ◽

2012 ◽

Vol 22 (2) ◽

pp. 195-201

Author(s):

Junko Kita ◽

Mami Tamai ◽

Kazuhiko Arima ◽

Yoshikazu Nakashima ◽

Takahisa Suzuki ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Tumor Necrosis Factor ◽

Poor Prognosis ◽

Tumor Necrosis ◽

Prognosis Factors ◽

Delayed Treatment ◽

Disease Modifying ◽

Patients with early rheumatoid arthritis who smoke are less likely to respond to treatment with methotrexate and tumor necrosis factor inhibitors: Observations from the Epidemiological Investigation of Rheumatoid Arthritis and the Swedish Rheumatology Reg

Arthritis & Rheumatism ◽

10.1002/art.27758 ◽

2010 ◽

Vol 63 (1) ◽

pp. 26-36 ◽

Cited By ~ 140

Author(s):

Saedis Saevarsdottir ◽

Sara Wedrén ◽

Maria Seddighzadeh ◽

Camilla Bengtsson ◽

Annmarie Wesley ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Tumor Necrosis Factor ◽

Tumor Necrosis ◽

Epidemiological Investigation ◽

The Effects of Tumor Necrosis Factor Inhibitors on Cardiovascular Risk in Rheumatoid Arthritis

Current Pharmaceutical Design ◽

10.2174/138161212799504786 ◽

2012 ◽

Vol 18 (11) ◽

pp. 1502-1511 ◽

Cited By ~ 24

Author(s):

Mike J.L. Peters ◽

Alper M. van Sijl ◽

Alexandre E. Voskuyl ◽

Naveed Sattar ◽

Yvo M. Smulders ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Cardiovascular Risk ◽

Tumor Necrosis Factor ◽

Tumor Necrosis ◽

Delay in imaging versus clinical response: A rationale for prolonged treatment with anti–tumor necrosis factor medication in early rheumatoid arthritis

Arthritis & Rheumatism ◽

10.1002/art.23097 ◽

2007 ◽

Vol 57 (8) ◽

pp. 1564-1567 ◽

Cited By ~ 50

Author(s):

Richard J. Wakefield ◽

Jane E. Freeston ◽

Elizabeth M. A. Hensor ◽

Domini Bryer ◽

Mark A. Quinn ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Tumor Necrosis Factor ◽

Clinical Response ◽

Tumor Necrosis ◽

Prolonged Treatment ◽

A Phase II Randomized Study of Subcutaneous Ixekizumab, an Anti-Interleukin-17 Monoclonal Antibody, in Rheumatoid Arthritis Patients Who Were Naive to Biologic Agents or Had an Inadequate Response to Tumor Necrosis Factor Inhibitors

Arthritis & Rheumatology ◽

10.1002/art.38617 ◽

2014 ◽

Vol 66 (7) ◽

pp. 1693-1704 ◽

Cited By ~ 137

Author(s):

Mark C. Genovese ◽

Maria Greenwald ◽

Chul-Soo Cho ◽

Alberto Berman ◽

Ling Jin ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Monoclonal Antibody ◽

Tumor Necrosis Factor ◽

Tumor Necrosis ◽

Randomized Study ◽

Biologic Agents ◽

Interleukin 17 ◽

Inadequate Response ◽

AB0379 Laboratory Safety of Adalimumab and Other Tumor Necrosis Factor Inhibitors in the Treatment of Rheumatoid Arthritis

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2014-eular.2051 ◽

2014 ◽

Vol 73 (Suppl 2) ◽

pp. 931-931 ◽

Cited By ~ 2

Author(s):

D.A. Pappas ◽

J.W. Shaw ◽

H. Chang ◽

M.A. Cifaldi ◽

G.W. Reed ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Tumor Necrosis Factor ◽

Tumor Necrosis ◽

Laboratory Safety ◽

Observational Studies on the Risk of Cancer Associated With Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis: A Review of Their Methodologies and Results

Yearbook of Medicine ◽

10.1016/j.ymed.2012.09.030 ◽

2012 ◽

Vol 2012 ◽

pp. 7-8

Author(s):

R.S. Panush

Keyword(s):

Rheumatoid Arthritis ◽

Tumor Necrosis Factor ◽

Observational Studies ◽

Tumor Necrosis ◽

Risk Of Cancer ◽